1h Free Analyst Time
The female sexual dysfunction treatment market is poised to grow by $7760.77 mn during 2023-2027, accelerating at a CAGR of 34.28% during the forecast period. The report on the female sexual dysfunction treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of chronic diseases, growing awareness of female sexual dysfunction, and approval and availability of drugs to treat hypoactive sexual desire disorder.
The female sexual dysfunction treatment market is segmented as below:
By Age Group
- Above 40 years
- Below 40 years
By Product
- Non-hormonal therapy
- Hormonal therapy
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the female sexual dysfunction treatment market covers the following areas:
- Female sexual dysfunction treatment market sizing
- Female sexual dysfunction treatment market forecast
- Female sexual dysfunction treatment market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Age Group
7 Market Segmentation by Product
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
List of Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the global female sexual dysfunction treatment market: Assos Ilac, Cipla Ltd., Dare Bioscience Inc., Dr Reddys Laboratories Ltd., Duchesnay Inc., Endo International Plc, Freya Pharma Solutions B.V., Lupin Ltd., Mithra Pharmaceuticals SA, Novo Nordisk AS, Palatin Technologies Inc., Pfizer Inc., Pharmbio Korea Inc., Sprout Pharmaceuticals Inc., Strategic Science and Technologies LLC, Teva Pharmaceutical Industries Ltd., and Viatris Inc.Commenting on the report, an analyst from the research team said: `The latest trend gaining momentum in the market is increasing r&d for treatment of sexual dysfunction in women.`
According to the report, one of the major drivers for this market is the increasing prevalence of chronic diseases.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Assos Ilac
- Cipla Ltd.
- Dare Bioscience Inc.
- Dr Reddys Laboratories Ltd.
- Duchesnay Inc.
- Endo International Plc
- Freya Pharma Solutions B.V.
- Lupin Ltd.
- Mithra Pharmaceuticals SA
- Novo Nordisk AS
- Palatin Technologies Inc.
- Pfizer Inc.
- Pharmbio Korea Inc.
- Sprout Pharmaceuticals Inc.
- Strategic Science and Technologies LLC
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
